A detailed history of Bellevue Group Ag transactions in Abb Vie Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 42,204 shares of ABBV stock, worth $7.19 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
42,204
Previous 27,593 52.95%
Holding current value
$7.19 Million
Previous $5.02 Million 44.07%
% of portfolio
0.12%
Previous 0.08%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $2.26 Million - $2.64 Million
14,611 Added 52.95%
42,204 $7.24 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $3.33 Million - $3.8 Million
20,866 Added 310.18%
27,593 $5.02 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $270,246 - $304,361
1,964 Added 41.23%
6,727 $1.04 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $188,495 - $218,211
-1,411 Reduced 22.85%
4,763 $709,000
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $1.46 Million - $1.81 Million
-11,002 Reduced 64.05%
6,174 $831,000
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $141,139 - $162,543
976 Added 6.02%
17,176 $2.74 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $110,233 - $132,198
-797 Reduced 4.69%
16,200 $2.62 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $2.17 Million - $2.49 Million
16,189 Added 2003.59%
16,997 $2.28 Million
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $42.8 Million - $54.4 Million
-310,692 Reduced 99.74%
808 $124,000
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $607,108 - $753,250
4,600 Added 1.5%
311,500 $50.5 Million
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $2.58 Million - $3.26 Million
24,000 Added 8.48%
306,900 $41.6 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $4.39 Million - $4.99 Million
-41,300 Reduced 12.74%
282,900 $30.5 Million
Q2 2021

Aug 12, 2021

SELL
$105.21 - $117.21 $6.3 Million - $7.02 Million
-59,900 Reduced 15.59%
324,200 $36.5 Million
Q1 2021

May 12, 2021

BUY
$102.3 - $112.62 $879,780 - $968,532
8,600 Added 2.29%
384,100 $41.6 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $27.2 Million - $36.8 Million
338,500 Added 914.86%
375,500 $40.2 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $851,092 - $1.14 Million
11,600 Added 45.67%
37,000 $3.63 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $1.1 Million - $1.67 Million
-17,100 Reduced 40.24%
25,400 $1.94 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $3.07 Million - $3.84 Million
42,500 New
42,500 $3.76 Million
Q1 2018

May 09, 2018

SELL
$92.01 - $123.21 $1.79 Million - $2.4 Million
-19,500 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $7.46 Million - $8.18 Million
-83,277 Reduced 81.03%
19,500 $1.89 Million
Q3 2017

Nov 13, 2017

SELL
$69.85 - $89.22 $824,020 - $1.05 Million
-11,797 Reduced 10.3%
102,777 $9.13 Million
Q2 2017

Aug 14, 2017

BUY
N/A
114,574
114,574 $8.31 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.